Person: ŞİMŞEK, MELİH
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Organizational Unit
Job Title
Last Name
ŞİMŞEK
First Name
MELİH
Name
19 results
Search Results
Now showing 1 - 10 of 19
- PublicationMetadata onlyPituitary Gland Metastasis of Breast Cancer: A Rare Case Report and Review of the Literature(2020-07-01T00:00:00Z) Şimşek, Melih; ŞİMŞEK, MELİH
- PublicationMetadata onlyMide kanserli hastaların demografik özelliklerinin sağ kalıma etkisi(2022-05-01T00:00:00Z) Karadeniz, Andaç; Bilici, Mehmet; Şimşek, Melih; ŞİMŞEK, MELİH
- PublicationMetadata onlyThe importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib(2021-08-01T00:00:00Z) YILMAZ, Ali; ŞİMŞEK, MELİH; HANNARİCİ, Zekeriya; Buyukbayram, Mehmet E.; BİLİCİ, Mehmet; Tekin, Salim B.; ŞİMŞEK, MELİHAim: To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). Patients & methods: A total of 150 patients with advanced HCC who were treated with sorafenib in our center between January 2011 and December 2019 were included in the study retrospectively. Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and GLR were analyzed to assess their prognostic value using Kaplan-Meier and Cox regression analysis before and after propensity score matching (PSM). Results: In univariate analysis before and after PSM, albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, prognostic nutritional index, AFP level and GLR were found to be significantly associated with both progression-free and overall survival. In multivariate analysis before and after PSM, GLR, albumin-bilirubin grade and AFP were determined to be independent prognostic factors for progression-free and overall survival. Conclusion: The GLR prior to sorafenib treatment is a new prognostic biomarker that may predict survival in advanced HCC.
- PublicationMetadata onlyEfficacy and safety of trastuzumab emtansine in Her2 positive metastatic breast cancer: real world experience.(2021-05-20T00:00:00Z) Bahçeci, Aykut; Paydaş, Semra; Ak, Naziye; Ferhatoğlu, Ferhat; Saip, Pınar Mualla; Seydaoğlu, Gülşah; Bilici, Mehmet; Şimşek, MELİH; Tekin, Salim Başol; Çalikuşu, Züleyha; Yavuz, Sinan; Şahin, Ahmet Bilgehan; Çubukçu, Erdem; Evrensel, Türkkan; Değirmencioğlu, Serkan; Demiray, Atike Gökçen; Yumuk, Perran Fulden; Alan, Özkan; Çikman, Duygu İlke; Demirelli, Fuat Hulusi; Köstek, Osman; Gökyer, Ali; Doğan, Mutlu; Bal, Öznur; Çakar, Burcu; Gökmen, Erhan; Yamaç, Deniz; Korkmaz, Taner; Aliyev, Altay; Keskin, Özge; Urvay, Semiha; Büyükşimşek, Mahmut; Karadeniz, Cemile; Yildiz, Birol; Yeşil Çinkir, Havva; Demir, Hacer; Beypinar, İsmail; Karaçin, Cengiz; Eser, Kadir; Baykara, Meltem; Kiliçkap, Saadettin; Okutur, Kerem; Bulut, Gülcan; Alkan, Ali; Arpaci, Erkan; Pilanci, Kezban Nur; Demir, Atakan; Işik, Deniz; Yildirim, Nilgün; ŞİMŞEK, MELİH
- PublicationMetadata onlyImmunological Agents Used in Cancer Treatment(2019-02-01T00:00:00Z) Simsek, MELİH; TEKİN, Salim Başol; BİLİCİ, Mehmet; ŞİMŞEK, MELİHImmune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), or PD-1 ligand (PD-L1). ICI are approved for the treatment of malign melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and renal cell carcinoma. They can lead to long-term anti-tumor responses by deactivating the brake mechanism in the immune system. Ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab are examples of ICI. CTLA-4 is a brake mechanism in immune response. Ipilimumab and tremelimumab are antibodies against CTLA-4. PD-1 is another important immune checkpoint co-inhibitor receptor that is expressed by activated T cells in the peripheral tissue. As a result of blockage of the PD-1/PD-L1 pathway, local tumor-specific immune response augments, and long-term tumor control can be achieved. In recent years, ICI are approved for the treatment of various malignities. They may be responsible for specific toxicities called immune-related adverse events (irAEs). irAEs are a consequence infiltration of normal tissues by activated T lymphocytes that are responsible for autoimmunity. Corticosteroids and anti-tumor necrosis factor agents, such as infliximab and mycophenolate mofetil, are effective in the treatment of irAEs. Immune checkpoint inhibition with monoclonal antibodies against CTLA-4 and/or PD-1/PD-L1 by single agent or combination treatments became a new option in various solid tumors. However, ICI have unique adverse events, and these adverse events should be considered in any new onset clinical situation and should be managed properly. Future prospective randomized clinical trials will clarify recent questions.
- PublicationMetadata onlyMalign mezotelyomada kemoterapi uygulamaları(2022-06-01T00:00:00Z) Şimşek, Melih; Işık, Ulaş; Gürbüz, Orkun; ŞİMŞEK, MELİH
- PublicationMetadata onlyMetachronous bilateral breast cancer diagnosed with primary breast lymphoma and mucinous carcinoma: The first case in the literature(2022-04-01T00:00:00Z) ŞİMŞEK, MELİH; Aykas, Fatma; Yildirim, Ahmet Ozgen; ŞİMŞEK, MELİH© 2022 Journal of Cancer Research and Therapeutics.Introduction: Breast cancer is the most common cancer in women and 2-11% of the cases are bilateral. Bilateral breast cancer frequently emerges as a second primary cancer. Lymphoma and mucinous carcinoma of breast are very rare. Here we present a case, of bilateral breast cancer with metachronous lymphoma and mucinous carcinoma. Case History: 57-year old female had received chemotherapy and radiotherapy for stage IA Diffuse Large B Cell Lymphoma (DLBCL) located in right breast. At 14th month of her breast DLBCL diagnosis, a diagnosis of mucinous carcinoma was determined in her left breast. After surgery, adjuvant anastrozole was initiated. The patient is still in follow-up with remission at her sixth year of DLBCL diagnosis and fifth year of mucinous carcinoma diagnosis. Conclusions: The evaluation of unilateral breast cancer patients in terms of bilateral breast cancer occurrence risk has become important.
- PublicationMetadata onlyMetastatic Breast Carcinoma Mimicking Urothelial Carcinoma(2022-06-01T00:00:00Z) Shbair, Abdallah T. M.; YASİN, Ayşe İrem; TOPÇU, Atakan; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİH; YASİN, AYŞE İREM; TOPÇU, ATAKAN; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİHBesides being the most frequently diagnosed cancer in women, breast cancer is the main cause of cancer-related deaths in this group of patients. Breast cancer frequently metastasizes to bone, lung, brain, and liver. Renal metastasis from the breast is extremely rare. Here we aimed to report a case of breast cancer with metastasis to bone and left renal pelvis. A 58-year old woman with a mass lesion in the left renal pelvis that mimicked urothelial carcinoma was referred to our clinic. The left nephroureterectomy procedure was performed, and the pathology revealed that a renal pelvis metastasis secondary to breast cancer.
- PublicationMetadata onlyA case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer(2021-06-01T00:00:00Z) TOPÇU, Atakan; YASİN, Ayşe İrem; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, Mesut; TÜRK, HACI MEHMET; TOPÇU, ATAKAN; YASİN, AYŞE İREM; SHBAIR, ABDALLAH T.M.; BEŞİROĞLU, MEHMET; ŞİMŞEK, MELİH; SUCUOĞLU İŞLEYEN, ZEHRA; YURTSEVER, İSMAİL; GÜCİN, ZÜHAL; ŞEKER, MESUT; TÜRK, HACI MEHMETIntroduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.
- PublicationMetadata onlyRelationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers(2019-06-01T00:00:00Z) Yildirim, Nilgun; Simsek, MELİH; Aldemir, Mehmet Naci; BİLİCİ, Mehmet; TEKİN, Salim Başol; ŞİMŞEK, MELİHObjective: We investigated the relationship between the maximum standardized uptake value (SUVmax) of whole-body positron emission tomography/computed tomography (PET/CT) performed before treatment and the demographical and histopathological features in locally advanced breast cancer (LABC), as well as the role of PET/CT in the evaluation of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC).